Macrolides: From Toxins to Therapeutics.
Lenz KD, Klosterman KE, Mukundan H, Kubicek-Sutherland JZ.
Toxins (Basel). 2021 May 12;13(5):347. doi: 10.3390/toxins13050347.
Clinical hepatotoxicity associated with antifungal agents.
Kyriakidis I, Tragiannidis A, Munchen S, Groll AH.
Expert Opin Drug Saf. 2017 Feb;16(2):149-165. doi: 10.1080/14740338.2017.1270264. Epub 2016 Dec 16.
[Macrolides and ketolides].
Cobos-Trigueros N, Ateka O, Pitart C, Vila J.
Enferm Infecc Microbiol Clin. 2009 Aug-Sep;27(7):412-8. doi: 10.1016/j.eimc.2009.06.002. Epub 2009 Jul 21.
A Review: Effects of Macrolides on CYP450 Enzymes.
Zhang L, Xu X, Badawy S, Ihsan A, Liu Z, Xie C, Wang X, Tao Y.
Curr Drug Metab. 2020;21(12):928-937. doi: 10.2174/1389200221666200817113920.
Clarithromycin-haltige H.-pylori-Therapie birgt höheres Risiko für akute neuropsychiatrische Ereignisse.
Plate A.
Praxis (Bern 1994). 2016 Sep;105(18):1103-4. doi: 10.1024/1661-8157/a002469.
Clarithromycin-induced hepatotoxicity.
Brown BA, Wallace RJ Jr, Griffith DE, Girard W.
Clin Infect Dis. 1995 Apr;20(4):1073-4. doi: 10.1093/clinids/20.4.1073.
Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19.
Hoang R, Temple C, Correia MS, Clemons J, Hendrickson RG.
Clin Toxicol (Phila). 2022 Dec;60(12):1350-1355. doi: 10.1080/15563650.2022.2134788. Epub 2022 Nov 14.
[Macrolides, ketolides and streptogramins].
Mensa J, García-Vázquez E, Vila J.
Enferm Infecc Microbiol Clin. 2003 Apr;21(4):200-7; quiz 208, 219.
Telithromycin.
Turner M, Corey GR, Abrutyn E.
Ann Intern Med. 2006 Mar 21;144(6):447-8. doi: 10.7326/0003-4819-144-6-200603210-00014.
Azithromycin-Induced Cholestatic Hepatitis.
Moy BT, Dojki FK, Scholes JV, Hoffman MG.
Conn Med. 2015 Apr;79(4):213-5.
